{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP02873",
    "Peptide Name": "Humimycin A (human microbiome mycin A, natural AMPs; lipopeptide; nonribosomal peptide; XXL; XXD2; microbiome, bacteria, prokaryotes; UCLL1c)",
    "Source": "human microbiota",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "YSYFTVV",
    "Sequence Length": 7,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Antifungal",
      "Anti-MRSA"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Unknown",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 0,
    "Boman Index": -0.68,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "42%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "APD analysis reveals that the sequence of this peptide shows 41.7% similarity toCn-AMP2.Chemical modification: Y3, T5 are D-amino acids. The N-terminus of the peptide is acylated with a C14 carbon fatty acid with hydroxylation at gamma carbon.Activity: Active against R. mucilaginosa (MIC 8 ug/ml), R. dentocariosa (MIC 16 ug/ml), Eubacterium spp. 3_1_31 (MIC 32 ug/ml), S. aureus MRSA (MIC 8 ug/ml), S. epidermidis (MIC 16 ug/ml), S. mitis (MIC 8 ug/ml), S. mutans (MIC 8 ug/ml), S. delphini (MIC 4 ug/ml), S. intermedius (MIC 8 ug/ml), S. pseudintermedius (MIC 4 ug/ml), S. pneumoniae (MIC 4 ug/ml), and S. sanguinis (MIC 16 ug/ml).Animal model:mouse: It  inhibits lipid II flippase and potentiate beta-lactam activity against MRSA in mice. The original synthetic peptide has been replaced. 9/2020; 7/2021; 4/2024",
    "Author": "Chu J, Vila-Farres X, Inoyama D, Ternei M, Cohen LJ, Gordon EA, Reddy BV, Charlop-Powers Z, Zebroski HA, Gallardo-Macias R, Jaskowski M, Satish S, Park S, Perlin DS, Freundlich JS, Brady SF. 2016",
    "Reference": "Nat Chem Biol . 2016 Dec;12(12):1004-1006. doi: 10.1038/nchembio.2207.PubMed",
    "Title": "Discovery of MRSA active antibiotics using primary sequence from the human microbiome"
  },
  "3D Structure": []
}